Join leading experts from the US and Europe in the pharmaceutical and biotech fields, who will explore the latest trends in drug development using New Approach Methodologies (NAMs).

This free event will cover topics such as drug discovery with AI and iPSC-derived cells, as well as new AI approaches for target identification – all explained with real-world case studies. Attendees will also gain insights on innovative overseas startups and scale-ups shaping the future of the industry.

Keynote speaker, Steve Chang from Simulations Plus, will highlight the frontiers of in silico approaches and the use of model-informed drug development (MIDD), incorporating perspectives from the US FDA. Ann Byrne from bit.bio will share the latest on the use of iPSC-derived cells, and Tom Pesnot from Concept Life Sciences will discuss accelerating target and hit identification through AI. Additionally, Corey Monteith from Intralink Boston will provide updates on the latest developments among US medtech startups.

After the presentations, participants are invited to enjoy networking and light refreshments.

Recommended for:

• Those who want to understand the latest trends in NAMs (New Approach Methodologies) for drug development
• Those interested in learning from the frontlines of US and European pharmaceutical companies and startups
• Those exploring new ventures in drug discovery involving AI and cell technologies

Event Details

Format: In-person seminar + networking

Audience: Executives and professionals from Japan’s leading pharmaceutical and life sciences companies

Participation fee: Free

Language: English (Q&A and networking in Japanese)

Access:

• JR “Shimbashi” Station, 7 min walk
• Toei Mita Line “Uchisaiwaicho” Station, 2 min walk
• Tokyo Metro Ginza Line “Toranomon” Station, 4 min walk
• Marunouchi/Hibiya/Chiyoda Lines “Kasumigaseki” Station, 7 min walk

Presenters: 

• Steve Chang – Global Head of Strategic Alliances, Business Development, Simulations Plus
• Ann Byrne – Business Development & Strategic Accounts Manager, bit.bio
• Tom Pesnot – Drug Discovery Services Director, Concept Life Sciences